Pfizer Inc. [PFE] is -19.39% lower this YTD. Is it still time to buy?

Pfizer Inc. [NYSE: PFE] price surged by 0.46 percent to reach at $0.22. The company report on November 11, 2022 that Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November 18, 2022 at 8:45 a.m. EST.

To view and listen to the webcast, visit our web site at Information on accessing and registering for the webcast will be available at beginning today.

A sum of 20902208 shares traded at recent session while its average daily volume was at 19.97M shares. Pfizer Inc. shares reached a high of $47.695 and dropped to a low of $46.31 until finishing in the latest session at $47.60.

The one-year PFE stock forecast points to a potential upside of 13.09.

Guru’s Opinion on Pfizer Inc. [PFE]:

SVB Leerink have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on May 23, 2022. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on April 06, 2022, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise from $59 to $70, while BofA Securities kept a Buy rating on PFE stock. On January 03, 2022, analysts increased their price target for PFE shares from 44 to 65.

The Average True Range (ATR) for Pfizer Inc. is set at 1.09, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 2.67. The Price to Book ratio for the last quarter was 2.88, with the Price to Cash per share for the same quarter was set at 6.47. Price to Free Cash Flow for PFE in the course of the last twelve months was 18.41 with Quick ratio for the last quarter at 1.40.

PFE Stock Performance Analysis:

Pfizer Inc. [PFE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.80. With this latest performance, PFE shares gained by 10.75% in over the last four-week period, additionally sinking by -4.65% over the last 6 months – not to mention a drop of -5.14% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 60.10, with the RSI for the last a single of trading hit 62.20, and the three-weeks RSI is set at 57.34 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 45.16, while it was recorded at 47.23 for the last single week of trading, and 49.27 for the last 200 days.

Insight into Pfizer Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +25.58 and a Gross Margin at +57.67. Pfizer Inc.’s Net Margin is presently recorded at +27.57.

Return on Equity for this stock inclined to 31.92, with Return on Assets sitting at 13.35.

Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.60.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to -3.30%.

Pfizer Inc. [PFE] Insider Position Details

There are presently around $184,689 million, or 70.40% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 488,445,127, which is approximately 1.958% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 435,152,528 shares of the stock with an approximate value of $20.71 billion in PFE stocks shares; and STATE STREET CORP, currently with $13.67 billion in PFE stock with ownership of nearly 0.126% of the company’s market capitalization.

Positions in Pfizer Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,465 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 215,091,820 shares. Additionally, 1,457 investors decreased positions by around 102,670,855 shares, while 357 investors held positions by with 3,562,255,550 shares. The mentioned changes placed institutional holdings at 3,880,018,225 shares, according to the latest SEC report filing. PFE stock had 111 new institutional investments in for a total of 7,955,329 shares, while 179 institutional investors sold positions of 18,153,487 shares during the same period.


Please enter your comment!
Please enter your name here